Addition of vandetanib to standard therapy (pegliposomal doxorubicin) in patients with recurrent ovarian cancer. A multi-centre, non-randomized, open phase I/randomized phase II study

Femme Homme

| Pays :
| Organes :
| Spécialités :

Extrait

to evaluate the tolerability and safety of once daily oral Vandetanib 100 mg when added to standard therapy (pegliposomal doxorubicin 50 mg/m2 iv every 4 weeks) compared to standard therapy alone (pegliposomal doxorubicin 50 mg/m2 iv every 4 weeks)

Critère d'inclusion

Ovarian Cancer

Liens

ictrp
euctr